- Dr. Ihle’s extensive background in chemistry, manufacturing and controls of antibody drug conjugate therapeutics will support the advancement of Bolt’s clinical program (BDC-1001) and its pipeline -
| REDWOOD CITY, Calif., April 2, 2020 /PRNewswire/ --Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced the appointment of Nathan Ihle, Ph.D., as vice president of chemistry, manufacturing and controls (CMC) and quality. Dr. Ihle will oversee and manage Bolt’s manufacturing, process and analytical development, and CMC regulatory strategies. He brings 18 years of CMC strategy and management experience to Bolt.
“Nathan has extensive knowledge about the development and commercialization of novel therapies to treat cancer,” said David Dornan, Ph.D., Bolt’s senior vice president of research. “He was instrumental in shepherding the antibody drug conjugate Adcetris (brentuximab vedotin) from the research phase through commercial approval, demonstrating a level of expertise that will be highly beneficial to Bolt as we advance our first clinical program. The addition of Nathan, along with the key hires made in 2019, strategically positions our team to build and advance the pipeline of our innovative Boltbody™ investigational products.” Dr. Ihle added, “I look forward to leading the effort as we build out our clinical supply chain and work toward commercialization of Boltbody™ ISACs for patients who have limited treatment options. Bolt’s technology platform has the potential to be applicable to a broad range of cancers and is promising for the future of cancer therapies.” Dr. Ihle was the founder and Principal at Ihle CMC Solutions. Prior to founding Ihle CMC Solutions, Dr. Ihle was the vice president of manufacturing strategy at Immunomedics, where he developed and implemented the supply strategy and supported the global commercialization of the company’s first antibody-drug conjugate product. He was also a key contributor to the company’s regulatory submissions. Before working at Immunomedics, Dr. Ihle worked for 16 years at Seattle Genetics as the vice president of CMC strategy and management. At Seattle Genetics, Dr. Ihle was responsible for CMC aspects of development and regulatory strategies for all corporate programs, portfolio and project management and alliance management. Dr. Ihle completed his post-doctoral work as an American Cancer Society Postdoctoral fellow at University of California, Berkeley after receiving his doctorate in Organic Chemistry from Stanford University. About Bolt Biotherapeutics’ Immune-Stimulating Antibody Conjugate (ISAC) Platform Technology About Bolt Biotherapeutics, Inc. Media Contacts: Investor Relations Contact:
SOURCE Bolt Biotherapeutics, Inc. |
View original content to download multimedia:
